POM-V Prescription Required

Rominervin 10 mg/ml Solution for Injection for Horses

Active ingredient: Romifidine Hydrochloride

Form

Injection

Species

Horses

Manufacturer

Le Vet Beheer B.V.

VMD MA No.

41821/4062

What it's used for

Sedative to facilitate handling, examination, minor surgical interventions and minor procedures. For premedication prior to administration of injectable or...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Romifidine Hydrochloride

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Rominervin 10 mg/ml Solution for Injection for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Sedative to facilitate handling, examination, minor surgical interventions and minor
procedures.
For premedication prior to administration of injectable or inhalation anaesthetics.
Romifidine can also be used with synthetic opiates (e.g. butorphanol) to provide
deeper sedation/analgesia.

For intravenous use.
A dose range of 0.04 – 0.12 mg romifidine HCl/kg bodyweight (0.4 – 1.2 ml
product/100 kg bodyweight) gives a dose-related response.
Onset of action, which is independent of dose, is 1 – 2 minutes. Maximum sedation is
achieved after 5 - 10 minutes. Please see the Table below.

Unlimited Renewal: March 2023
AN: 03396/2022
Recommended dose
Sedation
DoseDepth of Sedation
Duration of
Sedation
0.04 mg romifidine HCl/kg bw
(i.e. 0.4 ml product/100 kg bw)
Light0.5 - 1 hour
0.08 mg romifidine HCl/kg bw
(i.e. 0.8 ml product/100 kg bw)
Deep0.5 – 1.5 hours
0.12 mg romifidine HCl/kg bw
(i.e. 1.2 ml product/100 kg bw)
Deep sedation of
prolonged duration
At this dose
residual sedation
may persist for up
to 3 hours
When romifidine is used in combination with butorphanol for deeper sedation and
analgesia, a dose of 0.04 mg – 0.12 mg romifidine HCl/kg bw (0.4 – 1.2 ml product
per 100 kg bw) should be used followed by butorphanol.
Premedication
Premedication with ketamine for induction
When romifidine is used as premedication prior to ketamine induced anaesthesia, a
dose of 0.1 mg romifidine HCl/ kg bw (1 ml product/100 kg bw) should be used
followed by ketamine after 5-10 minutes.
Premedication with other agents for induction
When romifidine is used as premedication in combination with other agents such as
injectable or inhalation anaesthetics, a dose of 0.04 mg – 0.08 mg romifidine HCl/kg
bw (0.4 – 0.8 ml product per 100 kg bw) should be used followed by induction of
anaesthesia after 5-10 minutes.
Maintenance of anaesthesia
To maintain or deepen surgical anaesthesia with romifidine/ketamine, when facilities
for gaseous anaesthesia are not available, romifidine can be administered at a dose
of 0.025 mg/kg romifidine HCl (0.25 ml product/100 kg bodyweight) followed
immediately by ketamine intravenously (50% of the initial ketamine premedication
dose). Administer the romifidine/ketamine top-up dose immediately prior to
commencement of surgical incision or when signs of returning consciousness
appear.
The stopper should not be punctured more than 40 times

Do not use in horses in the last month of pregnancy.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use TMP/S-containing products intravenously when horses have been
sedated with romifidine.

Unlimited Renewal: March 2023
AN: 03396/2022

As with other veterinary medicinal products of this class, the following adverse events
may occur:
- Bradycardia, which may be profound
- Benign, reversible cardiac arrhythmias (second degree AV block and to a lesser
extent sino-atrial block)
- Hypotension, following a short period of hypertension
- Incoördination of the limbs/ataxia
- Sweating and increased salivation

Unlimited Renewal: March 2023
AN: 03396/2022
- Hyperglycemia and diuresis
- In male horses, a reversible, partial penile prolapse can occur.
- Increased sensitivity of the hind legs (defensive movements)
- In very rare cases mild symptoms of colic, as the intestinal motility is temporarily
inhibited.
Hypersensitivity may occur in very rare cases.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

None.

Special precautions for use in animals
Sedation with α2 agonist drugs, such as romifidine may increase the sensitivity of the
hind legs to tactile stimuli. Occasionally, defensive reactions, i.e. kicking, may occur
even in apparently well sedated animals.
The veterinary medicinal product should be used with caution in animals suffering
from cardiovascular or respiratory diseases, hepatic or renal insufficiency and in
animals in shock.
When used as a pre-anaesthetic agent, sedation should be apparent before the
induction of anaesthesia.
When the veterinary medicinal product is used as part of the anaesthetic procedure,
care should be taken during the recovery phase to ensure that the horse is kept in a
warm and quiet environment.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In the case of accidental oral intake or self-injection, seek medical advice
immediately and show the package insert to the physician but DO NOT DRIVE as
sedation and changes in blood pressure may occur.
Avoid skin, eye or mucosal contact.
Wash the exposed skin immediately after exposure with large amounts of water.
Remove contaminated clothes that are in direct contact with skin.
In the case of accidental contact of the product with eyes, rinse thoroughly with fresh
water. If symptoms occur, seek the advice of a physician.
If pregnant women handle the product, special caution should be observed not to
self-inject as uterine contractions and decreased foetal blood pressure may occur
after accidental systemic exposure.
Advice to the physician:
Romifidine is an alpha2-adrenoreceptor agonist, symptoms after absorption may
involve clinical effects including dose-dependent sedation, respiratory depression,
bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias
have also been reported. Respiratory and haemodynamic symptoms should be
treated symptomatically.

The sedative effect of the veterinary medicinal product may be potentiated by other
psychoactive compounds, such as tranquillisers, other sedatives or morphine-like
analgesics, therefore reducing the required dose of subsequent anaesthetic agents.
The concurrent intravenous use of potentiated sulphonamides with alpha2-agonists
has been reported to cause cardiac arrhythmias which may be fatal. Intravenous
administration of TMP/S containing products is therefore contra-indicated when
horses have been sedated with romifidine.
The concomitant use of romifidine and phenothiazines (e.g. acepromazine) can result
in severe hypotension.
The product should not be used in association with other substances belonging to the
same pharmacological class (sympathicomimetic amines, including alpha-2-agonist,
such as xylazine, detomidine..).

Keep the vial in the outer carton in order to protect from light.

Meat and offal: 6 days.
Not authorised for use in animals producing milk for human consumption.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.